Answers are grounded in this paper and cite their sources.
A 23-year-old man received denosumab therapy for histologically proven multiple pulmonary metastases from a giant cell tumor of the distal femur after surgery. Pulmonary metastases decreased in size six months after the initial denosumab administration. The toxicities of denosumab such as hypocalcemia and osteomyelitis of the jaw were not observed during the treatment period. Denosumab therapy resulted in the achievement of an objective response and disease stability for pulmonary metastases within five years of its initiation.
No takes yet. Share an insight, caveat, or question.
Kudawara et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: